Back

Sex differences in response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial

31 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Triple therapy in hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Patricia Guimaraes

Einstein Hospital Israelita, Sao Paulo (Brazil)

6 More presentations in this session

Presentation thumbnail
Initial triple low-dose combination therapy improves blood pressure control without increased adverse events: a systematic review and meta-analysis
Associate Professor J. Park (Goyang, KR)
Abstract
Presentation thumbnail
Treatment escalation beyond triple therapy in patients with resistant hypertension: a population-based observational cohort study from UK healthcare records
Doctor P. Swift (London, GB)
Abstract
Presentation thumbnail
Impact of baseline cardiovascular risk on hypertension treatment with a novel triple single-pill: a subanalysis of the OPTION TREAT Trial
Doctor V. Madrini (Sao Paulo, BR)
Abstract
Presentation thumbnail
Efficacy and safety of intensive versus standard systolic blood pressure treatment: A systematic review and meta-analysis
Associate Professor O. Rueda Ochoa (Bucaramanga, CO)
Abstract
Presentation thumbnail
Racial differences on treatment response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial
Doctor V. Madrini (Sao Paulo, BR)
Abstract

Access the full session

Session thumbnail
Triple therapy in hypertension

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Sex-based differences in treatment outcomes in HFpEF: a systematic review
28 August 2022
thumbnail
Congress Presentation
Blood pressure and LDL-cholesterol control in patients with primary hypertension is far from optimal: results from a large observational, multicentric, prospective study
1 September 2019
thumbnail
Congress Presentation
The differential effects of antihypertensive drugs on central blood pressure: nebivolol versus telmisartan (ATD-CBP)
28 August 2022
thumbnail
Congress Presentation
AIMHY-INFORM: Dual Therapy Arm
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources